Abeona Therapeutics (PCJ) Q3 2026 Earnings Report

The call was predominantly positive, driven by 18% sequential ZEVASKYN revenue growth, expansion to 8 qualified treatment centers, broad payer coverage, improving launch infrastructure, the acquisition of a differentiated Phase III-ready ABO-801 program and a sharply reduced net loss. The principal challenges were variable treatment timing, a ZEVASKYN out-of-specification batch, a planned shutdown affecting near-term treatment timing, higher cost of sales and SG&A, and the need to confirm that one additional ABO-801 Phase III study will satisfy FDA requirements.

Management expects ZEVASKYN treatment timing to remain variable through year-end, with some patients potentially moving into early 2027 for biopsy slots; biopsy collection will stop around mid-November and resume in mid-January, with about 6 weeks of performance in the first quarter and half of January and the month of Feb biopsies potentially converting into treatments in 1Q. ZEVASKYN manufacturing is currently at a capacity of 6 patients per month, with readiness to turn on additional capacity by mid-2027, reaching up to 10 manufacturing slots a month without additional clean-room construction; gross margins are anticipated to be about 85% to 90% at full manufacturing capacity utilization. For ABO-801, Abeona currently envisions enrolling approximately 400 patients in a Phase III study of 3 mg once daily versus placebo, plans to discuss the design at a Type C meeting, currently anticipates initiating the study in mid-2027 and results around end of 2028, with about 90% power based on a roughly 13% increase in responder rate; clinical development costs to FDA approval are estimated at about $50 million to $60 million, and peak annual revenue potential is greater than $750 million.